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Abstract: Bacterial degradation of toxic microcystins produced by cyanobacteria is a common
phenomenon. However, our understanding of the mechanisms of these processes is rudimentary.
In this paper several novel discoveries regarding the action of the enzymes of the mlr cluster
responsible for microcystin biodegradation are presented using recombinant proteins. In particular,
the predicted active sites of the recombinant MlrB and MlrC were analyzed using functional enzymes
and their inactive muteins. A new degradation intermediate, a hexapeptide derived from linearized
microcystins by MlrC, was discovered. Furthermore, the involvement of MlrA and MlrB in further
degradation of the hexapeptides was confirmed and a corrected biochemical pathway of microcystin
biodegradation has been proposed.
Keywords: microcystin; biodegradation; recombinant enzymes; biochemical pathway
1. Introduction
Cyanobacterial secondary metabolites including toxic microcystins (MCs) are subject to microbial,
mainly bacterial, degradation in natural water supplies. Several MC-degraders have been identified
in environmental samples [1]. However, the mechanism of MC biodegradation is poorly known
and the knowledge is limited to one partially-recognized biochemical pathway [2,3] which involves
three enzymes (MlrA, MlrB, and MlrC) encoded by the mlr gene cluster. The genome of several
Sphingomonas sp., Sphingophyxis sp., but also phylogenetically distinct, bacterial species were found
to contain homologues of the mlrA gene encoding the enzyme responsible for MC linearization,
a crucial step for toxin degradation [1]. On the other hand, in such MC-degrading strains as
Arthrobacter sp., Brevibacterium sp., Rhodococcus sp. [4], mlr genes were not detected. This could mean
that investigated strains do not possess mlr homologues, but this hypothesis requires experimental
verification. Regardless of the above, the mechanisms of MC-degradation in other bacterial strains
may be different and not limited to the proteins of mlr clusters. For example, the biodegradative
pathway of Methylobacillus sp. J10 [5] is probably based on enzymes bound to the cell wall or outside
the cytoplasmic membrane. Similarly, the contribution of the cell wall-associated proteinases was
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demonstrated indirectly during MC-removal by probiotic bacteria, e.g., Lactobacillus rhamnosus [6].
Apart from proteases, some other enzymes catalyzing decarboxylation, demethylation, deamination,
or dehydration reactions are possibly also involved in MC biodegradation [7,8]. However, such
hypotheses are based only on the detection of degradation products, since the respective enzymes have
not yet been characterized. Further studies of the mechanisms are needed to describe the alternative
reaction pathways and the involved proteins.
Knowledge (on the molecular level) about the process of MC utilization by the bacteria carrying
the mlr gene cluster is also limited. At present, neither final degradation products nor the order
of their formation are known. Recombinant MC-degrading proteins may be very helpful in the
investigation of the biochemical pathways and subsequent MC derivatives, and this approach
has been applied in this study. The aims of this work were to heterologously express MlrC and
MlrB derived from Sphingomonas sp., to identify and verify the putative active site of the studied
enzymes and to investigate the activity of the enzymes encoded by mlr cluster toward MC derivatives.
This approach allowed to specify the role of MlrB, MlrC, and MlrA in the bacterial utilization of
microcystin heptapeptides.
2. Results
2.1. Verification of Nucleotide Sequence Coding for MlrB
The sequence of mlrB gene was originally provided by Bourne et al. [3] (AF411069—original;
KR150744—revised; GenBank). Due to discrepancies of the MlrB sequence length with homologous
proteins in other bacteria, as well as previous experiences with the correction of MlrA [9], we
determined the sequence of the upstream mlrB using inverse PCR. By verification of sequencing
errors, causing frameshifts resulting in truncations of N- and C-terminals of MlrB, we provided
a full-length sequence which corresponds well with its homologues in Sphingopyxis sp. C-1 and
Sphingomonas sp. USTB-05 [10,11]. Numeration of amino acid residues was introduced consequently,
according to a postulated revised sequence of mlrB (Figure S1).
2.2. Recombinant MlrB, MlrC, and Their Mutants
Based on the SDS-PAGE analysis of the Escherichia coli BL21(DE3) cell lysates transformed with
pLATE31mlrB or pET21amlrC, it was observed that overexpressed recombinant MlrB and MlrC were
predominantly deposited in the insoluble fraction as inclusion bodies. Nevertheless, in the soluble
fraction, used for protein purification in native conditions, the enzymatic activity towards linearized
MCs could be detected indicating MlrB and MlrC in the supernatant. Furthermore, the addition of
15% glycerol into Luria-Bertani (LB) medium allowed to enrich the soluble fraction with both proteins
(approximately 10 times higher activity in comparison with soluble fraction of proteins after cultivation
without glycerol) and the presence of a significant amount of these enzymes was further confirmed
by Western blotting (Figure 1). MlrB muteins MlrBS77A and MlrBK80A were designed based on the
predicted active site [3]. Substitution of S77 and K80 residues with alanine residue abolished the
enzymatic activity of MlrB, which was demonstrated using acMC-LR and acMC-RR as a substrate
(Table 1). To verify the hypothesis (see Discussion for details) of the impact of three residues D167,
H169, and H191 on the activity of MlrC, the muteins MlrCD167A, MlrCH169A, and MlrCH191A were
prepared. The lack of activity of these muteins toward acMC-LR (Table 1) confirmed that the mutated
residues play the crucial role in the enzymatic activity of MlrB and MlrC.
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Table 1. The summarized results of the activity of Mlr enzymes and their muteins toward the 
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MC Derivatives MlrA MlrAH260A MlrB MlrBS77A MlrC MlrCH169A * Empty Plasmids 
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acMC-LF − − n.a. − + − − 
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acMC-YR − − n.a. − + − − 
hexaMC-LR + − + − − − − 
hexaMC-RR + − + − − − − 
tetrapeptide − − − − + − − 
n.a.—not analyzed in this study; * crude extracts and samples purified from total protein extract of  
E. coli cells transformed previously with empty plasmids. 
 
Figure 1. Western blot of soluble fraction of MlrC and MlrB proteins before induction (−IPTG) and 
after 7 h of cultivation with IPTG (+IPTG). 
2.3. MlrB and MlrC Purification 
The soluble fraction of MlrB was purified on a Ni-NTA column, which allowed an efficient 
binding of this enzyme. After isolation, to provide sufficient ionic strength and prevent protein 
precipitation, purified MlrB was dialyzed against PBS buffer. The calculated recovery of MlrB activity 
was 30% of the initial lysate. A similar attempt was made to purify MlrC. However, despite efficient 
binding to Ni-NTA, only about 12% of the initial lysate activity was recovered upon elution, 
suggesting partial inactivation of MlrC during purification. Since nickel ions have been shown to 
inhibit metalloproteases through substitution of the active center ion [12], we exchanged the nickel 
ions for cobalt. Using a Co-NTA column we were able to obtain a highly-active MlrC preparation 
recovering 63% of lysate activity. 
2.4. Activity of Recombinant MlrA, MlrB, and MlrC toward MC Derivatives 
Previously-unidentified products formed by hydrolysis of linearized variants of MC by MlrC 
were detected using a modified HPLC gradient (No 2). Increased hydrophilic conditions of 
separation and tracking the reaction products at 220 nm, typical for the peptide bond chromophore 
allowed to detect the molecules without the Adda-conjugated diene chromophore. Examples of 
HPLC chromatograms are shown in Figures 2 and S2. In addition to the peak corresponding to Adda 
(6.03 min), one new product with different retention time (depending on the acMC variants) was 
detected for each substrate used (Table 2). The MS analysis (indicating the m/z peaks 700.4 and 350.7) 
and MS/MS fragmentation pattern of acMC-LR derivative (Figure 3a) allowed recognition of this 
product as a hexapeptide Glu-Mdha-Ala-Leu-MeAsp-Arg, named hexaMC-LR (Figure 3b,c). The 
Figure 1. Western blot of soluble fraction of MlrC and MlrB proteins before induction (´IPTG) and
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Table 1. The summarized results of the activity of Mlr enzymes and their muteins toward the
derivatives of different MC variants.
MC Derivatives MlrA MlrAH260A MlrB MlrBS77A MlrC MlrCH169A * Empty Plasmids
acMC-LR ´ ´ + ´ + ´ ´
acdmMC-LR ´ ´ n.a. ´ + ´ ´
acMC-LF ´ ´ n.a. ´ + ´ ´
acMC-LW ´ ´ n.a. ´ + ´ ´
acMC-LY ´ ´ n.a. ´ + ´ ´
acMC-RR ´ ´ + ´ + ´ ´
acMC-YR ´ ´ n.a. ´ + ´ ´
hexaMC-LR + ´ + ´ ´ ´ ´
hexaMC-RR + ´ + ´ ´ ´ ´
tetrapeptide ´ ´ ´ ´ + ´ ´
n.a.—n t analyzed i this study; * crude extracts and samples purified from total protein extract of E. coli cells
transformed previously with empty plasmids.
2.3. MlrB and MlrC Purification
The soluble fraction of MlrB was purified on a Ni-NTA column, which allowed an efficient binding
of this enzyme. After isolation, to provide sufficient ionic strength and prevent protein precipitation,
purified MlrB was dialyzed against PBS buffer. The calculated recovery of MlrB activity was 30% of the
initial lysate. A similar attempt was made to purify MlrC. However, despite efficient binding to Ni-NTA,
only about 12% of the initial lysate activity was recovered upon elution, suggesting partial inactivation
of MlrC during purification. Since nickel ions have been shown to inhibit metalloproteases through
substitution of the active center ion [12], we exchanged the nickel ions for cobalt. Using a Co-NTA
column we were able to obtain a highly-active MlrC preparation recovering 63% of lysate activity.
2.4. Activity of Recombinant MlrA, MlrB, and MlrC toward MC Derivatives
Previously-unidentified products formed by hydrolysis of linearized variants of MC by MlrC were
detected using a modified HPLC gradient (No 2). Increased hydrophilic conditions of separation and
tracking the reaction products at 220 nm, typical for the peptide bond chromophore allowed to detect
the molecules without the Adda-conjugated diene chromophore. Examples of HPLC chromatograms
are shown in Figure 2 and Figure S2. In addition to the peak corresponding to Adda (6.03 min), one
new product with different retention time (depending on the acMC variants) was detected for each
substrate used (Table 2). The MS analysis (indicating the m/z peaks 700.4 and 350.7) and MS/MS
fragmentation pattern of acMC-LR derivative (Figure 3a) allowed recognition of this product as a
hexapeptide Glu-Mdha-Ala-Leu-MeAsp-Arg, named hexaMC-LR (Figure 3b,c). The fragments with
m/z 571.3, 553.3, and 488.3 were identical with those reported by Imanishi, et al. (2005) [13] and proved
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that the isolated product consists of at least five aa (Mdha-Ala-Leu-MeAsp-Arg), whereas the fragment
with m/z 682.3 is postulated to be Glu-Mdha-Ala-Leu-MeAsp-Arg with water loss. Depending on
the acMC variant used (Table 2), hexapeptides produced from other acMC variants had m/z values
as expected based on the calculation of their molecular masses and their fragmentation patterns
also corresponded to those obtained by the fragmentation of the hexaMC-LR derivative (Figure S3).
Based on this analysis, the cleavage site (peptide bond between Adda-Glu) of the linearized variants
was recognized.
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(a) 
Figure 2. HPLC chromatogram of linearized MC-LW after degradation by MlrC. Peaks with retention
times 2.73 min, 5.44 min, and 6.03 min correspond to hexaMC-LR, acMC-LR, and Adda, respectively.
Monitoring at 220 nm.
Table 2. Retention times and m/z values of linearized MC variants and their derivatives after hydrolysis
by MlrC. Asterisks indicate doubly-protonated ions.
Linearized Variants
of Different MC MC-LR dmMC-LR MC-LW MC-LF MC-RR MC-YR MC-LY
m/z of heptapeptides 1013.7 999.7 1043.6 1004.6 1056.5 528.9 * 1063.7 1020.6
retention time (min) 5.4 5.3 6.7 6.6 4.6 5.1 6.1
m/z of hexapeptides 700.4 350.7 * 686.4 343.7 * 730.4 691.4 372.3 * 750.4 375.7 * 707.4
retention time (min) 2.7 2.7 4.7 4.7 1.7 2.6 3.8
Second and third lines indicate m/z values and retention times of linear derivatives of MC, respectively. Fourth
and fifth lines indicate m/z values and retention times of hexapeptides derived from the hydrolysis of linear
MCs, respectively.
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Figure 3. (a) The structure of acMC-LR with historical numbering of amino acids which is maintained 
in this paper; (b) MS and MS2 analysis of the hexapeptide derived from acMC-LR; after fragmentation 
of the m/z 700.4, ions at m/z 682.3, 607.3, 488.3 were produced; and (c) the structure of hexapeptide 
derived from acMC-LR and the proposed fragmentation pattern. The indicated fragment ions have 
adequate ions in the MS2 of at least two other hexapeptide variants (according to the differences in 
their initial m/z values). 
Figure 3. (a) The structure of acMC-LR with historical numbering of amino acids which is maintained
in this paper; (b) MS and MS2 analysis of the hexapeptide derived from acMC-LR; after fragmentation
of the m/z 700.4, ions at m/z 682.3, 607.3, 488.3 were produced; and (c) the structure of hexapeptide
derived from acMC-LR and the proposed fragmentation pattern. The indicated fragment ions have
adequate ions in the MS2 of at least two other hexapeptide variants (according to the differences in
their initial m/z values).
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In the next step, the activity of MlrA, MlrB, and MlrC towards purified hexapeptides (hexaMC-LR
and hexaMC-RR) was tested. It was documented that the hexapeptides were not further degraded by
MlrC. On the other hand, a careful analysis of the hexapeptide concentration after incubation with
MlrA and MlrB documented that these products are hydrolyzed by these two enzymes (Table 1). This
observation was supported by assays with (a) known inhibitors of MlrA or MlrB and (b) mutated
MlrA [9] or MlrB. In the presence of phenanthroline (MlrA activity assay) and PMSF (MlrB activity
assay) and during incubation with muteins (MlrAH260A and MlrBS77A), the concentration of tested
hexapeptides did not change. In addition to above described analysis a tetrapeptide, another
well-known degradation product of MlrB, was purified and tested as a possible substrate of MlrA,
MlrB, or MlrC. It was observed that MlrA and MlrB were not active toward this product, while MlrC
released Adda from the tetrapeptide. Finally, both positive and negative results of enzymatic assays
allowed to obtain new information, which may be summarized as follows: (1) MlrB is able to hydrolyze
linearized heptapeptides derived from different MC variants independently on the amino acid residue
at position 2 (Leu in MC-LR, MC-LF, MC-LW, MC-LY, Arg in MC-RR and Tyr in MC-YR); (2) linearized
variants of several most common MCs are hydrolyzed by MlrC within the peptide bond between
Adda and Glu, resulting in Adda and hexapeptides as products; (3) the hexapeptides are not further
degraded by MlrC; but (4) are decomposed by MlrA and MlrB, however products have not been
detected; and (5) the tetrapeptide is not further degraded either by MlrA or MlrB. Based on these
findings we have introduced several corrections to the scheme of MC biodegradation (Figure 4).
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3. Discussion
3.1. Recombinant MlrB and MlrC—Verification of Sequence, Construction,
and Analysis of Muteins, Purification
r i s st i s f r i t lr [ ] fir t t t ti sit f t is r t i is l t
it i 260 I 265. The study of MlrB revealed that it is s ri r t s [ ] i s str
s c si il rit t rs f t icilli -r c i i f il , it t c s r ti
s ce Ser-Xa -Xa -Lys, and to a number of β-lactamases [3,14]. However, such activity of MlrB has
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not been documented to date. In the present study we have verified, experimentally, the predicted
active center of MlrB. The substitution of Ser (S77) and Lys (K80) with Ala residue completely abolished
the activity of the enzyme against linearized MCs. The studies of MlrC metalloprotease showed
that EDTA and o-phenantroline abolished enzymatic activity of this enzyme [2]. However, no
conservative motifs typical for metallopeptidases were found in the sequence of this protein. The
sequence comparison, performed using BLASTP algorithm (BLOSUM 62 matrix) indicated that MlrC
of Sphingomonas sp. ACM-3962 shows 24% identity and 40% sequence similarity with respect to
MlrC-like metallopeptidase (accession number in UniProt: Q11B79) derived from Mesorhisobium sp.
BNC1, with known crystallographic structure (Protein Data Bank database identifier: 3IUU). Structural
studies demonstrated that in a MlrC-like protein D138, H140, and H162 amino acid residues bind zinc
ions [15]. Interestingly, in MlrC of Sphingomonas sp. ACM-3962 the respective residues are present at
positions D167, H169, and H191. In order to verify the impact of these residues on the activity of MlrC,
three independent muteins MlrCD167A, MlrCH169A, and MlrCH191A were prepared. None of the tested
MlrC mutants exhibited an activity against linearized MCs and tetrapeptides, which confirmed that
the mutated residues play a crucial role in the enzymatic activity of MlrC. Moreover the requirement
of a divalent metal ion (presumably Zn2+) in the active site of MlrC has been indirectly confirmed
based on the previous report on the MlrC-like protein [15]. The analysis of MlrC purified using a
Ni-NTA column demonstrated that the majority of the initial enzyme activity was lost. In contrast to
this result, substantial improvement of enzyme activity was observed when the resin with immobilized
cobalt ions was used instead of Ni-NTA. A similar effect was observed during the purification of a
Zn-dependent metalloprotease, lysostaphin; application of the resin with immobilized cobalt ions
allowed for a substantial improvement of IMAC-based purification [12].
3.2. MCs Degradation Pathway
The first well-confirmed scheme of MCs degradation [2] assumed a sequential degradation of these
toxins by MlrA, MlrB, and MlrC enzymes encoded by genes of mlr cluster [3]. Three well-confirmed
intermediates of such degradation have been detected: acMC-LR, a tetrapeptide [2] (Figure 3b), and
Adda [16]. General knowledge concerning the activity of Mlr enzymes against MCs was as follows:
MlrA expresses activity toward cyclic MCs and nodularin (NOD) and it hydrolyzes the peptide bond
between Adda (position 5) and the amino acid residue at position 4, regardless of the MC variant,
causing linearization of molecules. MlrB is able to catalyze the hydrolysis of linearized MCs by cutting
the peptide bond between Ala (position 1) and a variable amino acid residue at position 2; however, the
resulting tetrapeptides originating only from MC variants with Leu at position 2 have been reported to
date [2,14,16,17]. MlrC releases Adda by hydrolysis of a peptide bond between Adda and Glu both in
the linearized heptapetide [18] and the tetrapeptide. Apart from Adda, several other MC degradation
products were also detected [19], mainly tri- and dipeptides. However the order of their formation
was not fully clarified and the involvement of particular enzymes was not addressed in that study.
Finally, the general opinion was that MCs are linearized by a very specific MlrA enzyme, and then the
heptapeptides are completely degraded by MlrB and MlrC to single amino acids. In the current study
we are presenting more comprehensive data concerning the role of enzymes encoded by the mlr gene
cluster in further utilization of linearized MCs.
Among different MC-LR degradation products hexapeptides have never been predicted nor
detected and our findings constitute the first report of the formation of such products as a result of
MlrC activity. In wild strains, these intermediates are probably hydrolyzed immediately by other
enzymes. It may be the reason why hexapeptides have never been detected when MCs biodegradation
was investigated using wild bacterial strains. The use of single enzymes allowed us to recognize these
intermediates and to verify activity of studied proteins.
The documented activity of MlrC sheds new light on the specificity of this enzyme. Previously [18],
we found Adda as the only degradation product of linearized heptapeptide hydrolysis and we
suggested that MlrC is less specific and can hydrolyze other bonds of linearized MC derivatives,
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producing small peptides and amino acids. Current research strongly supports the hypothesis that
MlrC can hydrolyze only one peptide bond within acyclic MCs (between Adda and Glu) which was
assumed from the fact that the hexapeptides (regardless MC variant they came from) are not further
degraded by MlrC.
On the other hand, the hexpeptides are degraded both by MlrA and MlrB. The hydrolysis products
were not detected. Nevertheless we postulate (based on the analysis of the degradation of several
acyclic MC variants) that MlrB may be active toward Ala-X bond (where X denotes a variable amino
acid at position 2 in different variants of MC), which results in the formation of two tripeptides
(Glu-Mdha-Ala and X-(Me)Asp-Z). This also implies that the tripeptide Adda-Glu-Mdha documented
by Hashimoto, et al. (2009) [19] is formed neither by MlrB nor MlrC. Most surprising, however, is
the finding of MlrA activity against the hexapeptide (regardless of the MC variant). To date, only
cyclic toxins have been proved to be a substrate for this enzyme. Among 50 tested fluorogenic
and chromogenic synthetic substrates, none were hydrolyzed by MlrA [9]; hence, this protease was
suggested to be very specific. The current results shed new light on the role of MlrA in complete
utilization of MCs.
Adda is known to determine the protein phosphatase (1 and 2A) inhibition capacity of MCs and
related pentapeptide NOD [20]. It has been demonstrated that this amino acid induces the expression of
mlrA and mlrB genes [21] and plays an important role in the bacterial decomposition of MCs. Moreover,
the authors concluded that Adda is a key signaling molecule involved in cell-to-cell communication.
Our results provide new arguments supporting this hypothesis. We indicated that both MlrA and
MlrC are active toward MCs, or their fragments as long as they contain Adda. Moreover, MlrC cleaves
only the peptide bond between Adda and Glu. However, hydrolysis is possible only after previous
linearization of heptapeptides by MlrA. The latter recognizes the peptide bond at the N-terminal site of
Adda independently on the variable amino acid residue at position 4. On the other hand, other peptide
bonds of hexapeptides may be also hydrolyzed by this enzyme, but only when Adda is removed by
MlrC; however, details of this phenomenon are currently unknown.
Some of the above-mentioned proposals require experimental confirmation but our hypothesis is
that the final products of MlrB and MlrC activity toward linearized MCs are Adda, Glu-Mdha-Ala, and
X-MeAsp-Z. It leaves open the question whether these two tripeptides are utilized by MlrA or/and
other enzymes, not encoded in the mlr cluster. To answer the question, it is necessary to detect and
purify new degradation products which can be subsequently tested to determine whether they are
susceptible to Mlr enzymes. If not, it would open the area of investigation of the other enzymes of
Sphingomonas sp. involved in complete utilization of MCs.
Safety plans of World Health Organization regarding treatment strategies for the mitigation of
cyanobacteria and their metabolites assume the development of many options of water purification
which also include biological treatment. Academic research of the mechanism of bacterial degradation
of MCs allow to deepen our knowledge in this area. Such advanced research conducted simultaneously
with environmental studies help in better understanding the phenomenon of MCs’ biodegradation
and should result in more relevant application studies.
4. Materials and Methods
4.1. Chemicals and Bacterial Strains
Trifluoroacetic acid (TFA) was obtained from Sigma (St Louis, MO, USA); C18 Purospher column
and acetonitrile (ACN) were obtained from Merck (Darmstadt, Germany). pTZ57R/T cloning
vector, expression vector pLATE31, Phusion High-Fidelity DNA Polymerase, T4 DNA ligase, NdeI
and NotI were obtained from Thermo Fisher Scientific (Waltham, MA, USA); E. coli BL21(DE3)
and expression vector pET21a from Novagen (Darmstadt, Germany). Monoclonal antibodies and
peroxidase-conjugated secondary antibodies were from Sigma (St Louis, MO, USA). Linearized MC
variants were produced from cyclic forms by the method described earlier [9]. MC-LR and dmMC-LR
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were extracted and purified from a culture of Microcystis aeruginosa PCC 7813 strain (the Pasteur
Institute, Paris, France) [22]. MC-LW, MC-LF (extracted from M. aeruginosa PCC7820), MC-RR, MC-LY,
and MC-YR (Microcystis NIES 107) were HPLC purified as described by Meriluoto and Spoof [23]. MlrA
used in this study was expressed in E. coli BL21 pET21amlrA and purified as described previously [9].
All acyclic MCs were produced by linearization of cyclic MC variants by MlrA, whereas tetrapeptide
was produced from acMC-LR by MlrC. These products were purified by HPLC followed by MS
analyses (description in Section 4.7).
4.2. Verification of MlrB Coding Sequence
To determine DNA sequence upstream mlrB coding sequence inverse PCR method has been
used. Briefly, genomic DNA from Sphingomonas sp. ACM-3692 has been digested with NcoI and
subsequently purified with CleanUp (A & A Biotechnology, Gdynia, Poland). The digested DNA was
circularized with T4 DNA ligase. Aliquots of the ligation mixture were used as a template in inverse
PCR with primers InvBF and InvBR pointing outwards (Table 3).
Table 3. Primers used in the construction of recombinant plasmids and mutagenesis. Artificial
sequences facilitating cloning to pLATE and pET21 are italized, codon introducing mutations are
bolded. InvBF and InvBR primers were used in inverse PCR.





mlrBS77AF CTTCGAGTTGGCGGCAACATCGAAGC ~6124 *
mlrBS77AR GCTTCGATGTTGCCGCCAACTCGAAG




mlrCD167AF GGGGCCGAACTTGCTCTTCACGCTCAC 6947 *
mlrCD167AR GTGAGCGTGAAGAGCAAGTTCGGCCCC
mlrCH169AF GAACTTGATCTTGCCGCTCACTTGTCG 6947 *
mlrCH169AR CGACAAGTGAGCGGCAAGATCAAGTTC
mlrCH191AF CAAGTACTATCCGGCTATCGACTACGTC 6947 *
mlrCH191AR GACGTAGTCGATAGCCGGATAGTACTTG
* primers were used in site directed mutagenesis method, the whole plasmid containing insert with substituted
codon was amplified.
4.3. Construction of Recombinant Plasmids, Including Mlrb and Mlrc and Their Mutants
MlrB and mlrC ORFs were amplified using Sphingomonas sp. ACM-3692 genomic DNA as
a template. After amplification with mlrBF and mlrBR primers (Table 3), mlrB was inserted into
pLATE31 vector using an aLICator Ligation Independent Cloning and Expression System (Thermo
Fisher Scientific, Waltham, MA, USA) according to the manufacturer’s instruction. The resulting
plasmid (pLATE31mlrB) encodes full-length MlrB (541 amino acid residues) with a six-histidine tag
added to C-terminus. The amplified mlrC fragment was inserted into a pTZ57R/T cloning vector,
cut out using NdeI and NotI restriction enzymes, and inserted into the expression vector pET21a.
The resulting plasmid pET21amlrC encodes full length MlrC (507 amino acids) with a His tag on
its C-terminal. Particular muteins were prepared based on the initial constructs pLATE31mlrB and
pET21amlrC by site-directed mutagenesis method. Codons selected for the mutagenesis were replaced
with codon for alanine introduced with primers (Table 4). The PCR was carried out with a primer pair
introducing a mutation (Table 3) and Phusion polymerase.
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Table 4. Amino acid residues and respective codons exchanged in MlrB and MlrC mutant studies.
Protein
Substituted Introduced
Residue Codon Residue Codon
MlrB
S77 TCA A77 GCA
K80 AAG A80 GCG
MlrC
H167 GAT A167 GCT
D169 CAC A169 GCC
H191 CAT H191 GCT
4.4. Expression of Recombinant MlrB and MlrC
Competent E. coli BL21(DE3) cells were transformed with pET21amlrC, pET21amlrCD167A,
pET21amlrCH169A, pET21amlrCH191A, pLATE31mlrB, pLATE31mlrBS77A, or pLATE31mlrBK80A
plasmids and plated on LB agar plates containing ampicillin (100 µg¨ mL´1). As a negative control,
E. coli BL21(DE3) transformed with pET21a or pLATE31 were used. A single colony was inoculated
into liquid LB medium supplemented with 15% glycerol and with ampicillin (100 µg¨ mL´1), and
grown at 37 ˝C with vigorous shaking. When the culture reached OD600 = 0.8 the expression of
cloned genes was induced by the addition of isopropyl β-D-1-thiogalactopyranoside (IPTG, from Lab
Empire S.C., Rzeszow, Poland) to a final concentration of 1 mM. Next, the temperature was reduced
to 22 ˝C and the cells overexpressing MlrB and MlrC were grown for 20 h. Subsequently, the bacteria
were centrifuged and the pellet was stored at ´20 ˝C until use.
4.5. Purification of Recombinant MlrB and MlrC
The purification based on Ni-NTA (Qiagen, Hilden, Germany) was applied using conditions
similar to these recommended by the supplier. Upon centrifugation, the E. coli BL21(DE3) cells
were suspended in a lysis buffer (50 mM NaH2PO4, 300 mM NaCl, pH 8.0), sonicated, followed
by centrifugation. The supernatants containing recombinant MlrB and MlrC (or lysates deriving
from cells carrying empty plasmids as negative control) were loaded into the Ni-NTA and Co-NTA
column, respectively. Co-NTA was prepared from Ni-NTA by removing nickel ions (washing with
100 mM EDTA, pH 8.0) and loading cobalt ions (washing the column with 100 mM CoCl2). After
loading, the columns were washed with lysis buffer and then recombinant proteins were eluted
with elution buffer containing 250 mM imidazole. Protein-containing fractions were immediately
dialyzed against PBS, pH 7.0 (MlrB) or 50 mM phosphate buffer, pH 7.0 (MlrC). SDS-PAGE [24]
was used to analyze protein expression (soluble and insoluble fractions) and the purification
process. Western blot was used to confirm protein expression in soluble fractions. Briefly, upon
electrophoresis proteins were electrotransfered onto polyvinylidene fluoride (PVDF) membrane with
10 mM 3-(cyclohexylamino)-1-propanesulfonic acid pH 11.0. The membrane was incubated with
anti-His tag monoclonal antibodies. After incubation with the peroxidase-conjugated secondary
antibodies the blot was developed using BCIP/NBT as a substrate.
4.6. Activity Assays
The E. coli pellet was suspended in 50 mM sodium phosphate pH 7.0 (1/20 volume of bacterial
culture) and the cells were disrupted by sonication. Acyclic MC-LR (acMC-LR) and linearized variants
originating from other MCs were used to test the activity of the MlrA, MlrB, MlrC, and their mutated
forms. Ten µL of the E. coli lysate or purified enzyme in serial dilution was added to 90 µL of acMC-LR
or other MC derivative (1.0 µg¨ mL´1) in 50 mM phosphate buffer, pH 7.0. The samples were incubated
at 20 ˝C for 1 h and the reaction was stopped by addition of 10 µL of 1% TFA. The production of
tetrapeptide and Adda from acMC-LR by MlrB and MlrC, respectively, was monitored by HPLC.
MlrA, MlrB, and MlrC activity towards different MC derivatives (hexapeptides and tetrapeptide)
was performed as described above with some modification of substrate concentration and time of
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reaction, depending on the experiment. To confirm the MlrA and MlrB activity towards hexapeptides
derived from acMC-LR and acMC-RR, three types of negative control were used: (1) mutated
enzymatically-inactive MlrA [9], MlrB, and MlrC muteins, (2) crude extracts, and (3) samples purified
from total protein extract of E. coli cells transformed previously with empty plasmids. Additionally,
control assays were performed in the presence of o-phenantroline (inhibitor of metallopeptidases)
or phenylmethanesulfonyl fluoride (PMSF, inhibitor of serine proteases) with a final concentration
of 20 mM and 4 mM, respectively. The lack of activity was confirmed by the lack of changes in the
substrate concentration.
4.7. HPLC and Mass Spectrometry
HPLC analyses, including the identification of the degradation products of acMCs, were
performed using an Agilent 1220 Infinity Gradient DAD LC System (Aglient Technologies, Santa
Clara, CA, USA) including gradient pump with an integrated degassing unit, autosampler, column
oven, and diode array detector. MC degradation products were separated and quantified using a
Purospher STAR RP-18 endcapped column (55 mm ˆ 4 mm, 3 µm particles). The mobile phase
consisted of a gradient of 0.05% aqueous TFA (solvent A) and 0.05% TFA in acetonitrile (solvent B).
Most of the assays were performed with the following linear gradient program (Number 1): 0 min
25% B, 5 min 70% B, 6 min 70% B, and 6.1 min 25% B. Additionally, to detect the hexapeptides, the
following gradient program (Number 2) was applied: 0 min 5% B, 8 min 70% B, 9 min 70% B, and 9.1
min 5% B. Fractions obtained from HPLC separations were evaporated to dryness and dissolved in
30% methanol with 0.1% HCOOH. Samples were analyzed using a HCTultra ETDII mass spectrometer
(Bruker, Bremen, Germany). The system was operated with a syringe pump (KD Scientific, Holliston,
MA, USA) at a flow rate of 3 µL¨ min´1 and direct injection of samples to an electrospray ionization
(ESI) ion source. The ESI was operated in the positive ion mode, at the capillary voltage of 3.5 kV,
nebulizer pressure of 10 psi, drying gas flow of 5 L¨ min´1 and ion source temperature of 300 ˝C. The
ion trap (IT) analyzer performed both MS and MS2 (tandem mass spectrometry) analyses. Peptide
identification was performed manually using DataAnalysis™ 4.0 software (Bruker, Bremen, Germany).
Supplementary Materials: The following are available online at www.mdpi.com/2072-6651/8/3/76/s1.
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Abbreviations
The following abbreviations are used in this manuscript:
acMCs (linearized) acyclic microcystins
Adda 3-amino-9-methoxy-2,6,8-trimethyl-10-phenyl-deca-4,6-dienoic acid
BLAST Basic Local Alignment Search Tool
Co-NTA Ni-NTA column with nickel ions replaced with cobalt ions
hexaMCs hexapeptides produced from acyclic MCs
HPLC high performance liquid chromatography
IPTG isopropyl β-D-1-thiogalactopyranoside
m/z mass to charge ratio




ORFs open reading frames
PCR polymerase chain reaction
PMSF phenylmethanesulfonyl fluoride
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